U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf

Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.

Originator

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
BACITRACIN

Approved Use

Uses first aid to help prevent infection in: •minor cuts •scrapes •burns

Launch Date

1948
Curative
Approved
8583
CORTISPORIN

Approved Use

For the treatment of corticosteroid-responsice dermatoses with secondary infection.

Launch Date

1957
Curative
Approved
8583
NEOSPORIN

Approved Use

NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

Launch Date

1968
PubMed

PubMed

TitleDatePubMed
Bacitracin Inhibits the Migration of U87-MG Glioma Cells via Interferences of the Integrin Outside-in Signaling Pathway.
2016-03
Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation.
2004-04
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants.
2004-03
Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase.
2003-12-05
Regulated cell surface pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process.
2003-11-14
Zinc modulates mRNA levels of cytokines.
2003-11
Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family.
2003-10-03
Prion, amyloid beta-derived Cu(II) ions, or free Zn(II) ions support S-nitroso-dependent autocleavage of glypican-1 heparan sulfate.
2003-10-03
Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters.
2003-10-01
Zinc modulates PPARgamma signaling and activation of porcine endothelial cells.
2003-10
O6-alkylguanine-DNA alkyltransferase: low pKa and high reactivity of cysteine 145.
2003-09-23
Purification of recombinant human apometallothionein-3 and reconstitution with zinc.
2003-09
The acrodermatitis enteropathica gene ZIP4 encodes a tissue-specific, zinc-regulated zinc transporter in mice.
2003-08-29
Redox labile site in a Zn4 cluster of Cu4,Zn4-metallothionein-3.
2003-08-19
Mechanisms of Zn(2+)-induced signal initiation through the epidermal growth factor receptor.
2003-08-15
Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells.
2003-08-01
Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts.
2003-08
Chromium(VI) down-regulates heavy metal-induced metallothionein gene transcription by modifying transactivation potential of the key transcription factor, metal-responsive transcription factor 1.
2003-07-11
Differential effects of zinc on functionally distinct human growth hormone mutations.
2003-07
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites.
2003-06
Zinc accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors is accompanied by an altered expression of ZnT-1 and metallothionein.
2003-06
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase.
2003-05-02
Interrelationships among brain, endocrine and immune response in ageing and successful ageing: role of metallothionein III isoform.
2003-04
Effect of chromium on apolipoprotein A-I expression in HepG2 cells.
2003-04
Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays.
2003-04
Copper reduction by copper binding proteins and its relation to neurodegenerative diseases.
2003-03
Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes.
2003-02-15
Effects of zinc occupancy on human O6-alkylguanine-DNA alkyltransferase.
2003-02-04
A novel class of ligand-gated ion channel is activated by Zn2+.
2003-01-10
p53 deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice.
2003-01-01
Activation of the rainbow trout metallothionein-A promoter by silver and zinc.
2003-01
The permissive effect of zinc deficiency on uroguanylin and inducible nitric oxide synthase gene upregulation in rat intestine induced by interleukin 1alpha is rapidly reversed by zinc repletion.
2003-01
Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice.
2003-01
Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle.
2002-12-13
Isolation of GIF from porcine brain and studies of its zinc transfer kinetics with apo-carbonic anhydrase.
2002-12
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents.
2002-11
Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation.
2002-11
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation.
2002-10
[Effect of zinc deficiency and zinc replenishment on HOX3.5 gene expression in mouse embryos].
2001-11
Detection by HPLC-ICP of metallothionein in serum of an epileptic child with valproate-associated hepatotoxicity.
1992-12
Differential dephosphorylation of the insulin receptor and its 160-kDa substrate (pp160) in rat adipocytes.
1992-07-15
In vitro sensitivity of Bacillus proteus and Pseudomonas aeruginosa to seven antibiotics; penicillin, streptomycin, bacitracin, polymyxin, aerosporin, aureomycin, and chloromycetin.
1950-02
Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene.
1950-02
The Use of Bacitracin in Experimental Clostridium Welchii Infection in Guinea Pigs.
1949-10
IN VITRO STUDIES ON POSSIBLE SYNERGISTIC ACTION BETWEEN PENICILLIN AND BACITRACIN.
1949-09
The Results of the Systemic Administration of the Antibiotic, Bacitracin, in Surgical Infections: A Preliminary Report.
1948-10
A Note on the Susceptibility of Hemophilus influenzae Type B to Bacitracin.
1948-10
The relative antisyphilitic activity of penicillins F,G,K, and X and of bacitracin, based on the amounts required to abort early syphilic infections in rabbits.
1948-03
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo.
1948-03
Bacitracin: Methods of Production, Concentration, and Partial Purification, with a Summary of the Chemical Properties of Crude Bacitracin.
1948-02
Patents

Patents

03943143
6
03959300
5
03959322
53
03965108
5
03983245
10
03989685
8
03991123
8
04039353
5
04061771
13
04080330
6
04138410
12
04147693
6
04166131
12
04166816
10
04194049
5
04234517
7
04262000
6
04262013
6
04276363
5
04307243
5
04308208
9
04331676
11
04347246
6
04374139
5
04382949
5
04400492
8
04440685
13
04443365
9
04443631
5
04481142
5
04497738
7
04497817
6
04505911
5
04515948
7
04518603
5
04525361
16
04543430
5
04544458
5
04549192
5
04568782
5
04570171
6
04622403
5
04654363
6
US2498165
5
US2834711 A
5

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration: Topical
In Vitro Use Guide
The MIC value was 32 mg/L for Staphylococcus aureus wild type strain after 48h incubation at 37°C.
Substance Class Mixture
Created
by admin
on Mon Mar 31 18:18:13 GMT 2025
Edited
by admin
on Mon Mar 31 18:18:13 GMT 2025
Record UNII
89Y4M234ES
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BACITRACIN ZINC
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
LANABIOTIC COMPONENT BACITRACIN ZINC
Preferred Name English
NEO-POLYCIN COMPONENT BACITRACIN ZINC
Common Name English
BACITRACIN ZINC [GREEN BOOK]
Common Name English
BACITRACIN ZINC [MART.]
Common Name English
BACITRACIN ZINC [VANDF]
Common Name English
BACITRACIN ZINC [USP-RS]
Common Name English
BACITRACIN ZINC [EP MONOGRAPH]
Common Name English
POLYSPORIN COMPONENT BACITRACIN ZINC
Common Name English
Bacitracins zinc complex
Common Name English
BACITRACIN ZINC [WHO-IP]
Common Name English
BACITRACIN ZINC [USP MONOGRAPH]
Common Name English
BACITRACIN ZINC [MI]
Common Name English
BACITRACIN ZINC [ORANGE BOOK]
Common Name English
ZINC BACITRACIN
Common Name English
NOPTRACIN
Common Name English
BACITRACINUM ZINCUM [WHO-IP LATIN]
Common Name English
BACIFARMIN
Common Name English
Bacitracin zinc [WHO-DD]
Common Name English
BACITRACINS, ZINC COMPLEX
Common Name English
ZIBA-RX
Brand Name English
OCUMYCIN COMPONENT BACITRACIN ZINC
Common Name English
Classification Tree Code System Code
CFR 21 CFR 333.120
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
CFR 21 CFR 558.78
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
NCI_THESAURUS C258
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
CFR 21 CFR 333.110
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
CFR 21 CFR 558.78
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
EPA PESTICIDE CODE 6309
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
CFR 21 CFR 520.154C
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
Code System Code Type Description
EVMPD
SUB00653MIG
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-787-8
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
RS_ITEM_NUM
1048007
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
BACITRACIN ZINC
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Soluble in 900 parts of water and in 500 parts of ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Antiinfective drug. Storage: Bacitracin zinc should be kept in a tightly closed container, protected from light, and stored at a temperature not exceeding 25 ?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude microorganisms. Labelling: The designation sterile Bacitracin zinc indicates that the substance complies with the additional requirements for sterile Bacitracin zinc and may be used for other sterile applications. Additional information: Bacitracin zinc is hygroscopic. Definition: Bacitracin zinc is a zinc complex of bacitracin, a polypeptide produced by the growth of an organism of the licheniformis group of Bacillus subtilis. The main components are Bacitracin A, B1 and B2. Bacitracin zinc contains not less than 55 International Units of bacitracin per mg, calculated with reference to the dried substance.
CAS
1405-89-6
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
NCI_THESAURUS
C28857
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
MERCK INDEX
m2199
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY Merck Index
FDA UNII
89Y4M234ES
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
DRUG BANK
DBSALT001356
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200558
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
DAILYMED
89Y4M234ES
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID00858760
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
SMS_ID
100000090427
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY
RXCUI
11417
Created by admin on Mon Mar 31 18:18:13 GMT 2025 , Edited by admin on Mon Mar 31 18:18:13 GMT 2025
PRIMARY RxNorm
All of the following components must be present:
Structure of BACITRACIN B3 ZINC
Structure of BACITRACIN A ZINC
Structure of BACITRACIN B1 ZINC
Structure of BACITRACIN B2 ZINC
Related Record Type Details
Bacitracin
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.41.pdf
Definition References
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966